{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Section No. and name Description of change', 'Brief rationale', 'And', 'Section 10.1.10 Visit 16/M12', '(second course of', 'alemtuzumab)', 'Section 9.3.1 Adverse', 'Added thrombocytopenia and myocardial infarction in assessment of', 'Update of the safety', 'events', 'IARs', 'information', 'Section 10.1.4 Visit 4/M0/D1', 'Updated the pre-infusion text:', 'Update of patient', '(first course of', 'The following infusion management procedures must be utilized for', 'monitoring and safety', 'alemtuzumab)', 'each infusion and each treatment course to reduce serious reactions', 'procedures', 'And', 'temporally associated with alemtuzumab infusion:', 'Section 10.1.10 Visit 16/M12', 'Pre-infusion: Physicians should obtain a baseline ECG and', '(second course of', 'vital signs (including heart rate and blood pressure measurement),', 'alemtuzumab)', 'screen for pre-existing hemorrhagic, cardiovascular (including', 'venous thromboembolism) and cerebrovascular risk factors, screen', 'for lung disease, review concomitant medications (eg, antiplatelet', 'agents, anticoagulants), perform laboratory tests (complete blood', 'count with differential, serum transaminases, serum creatinine, test', 'of thyroid function and urinalysis with microscopy), and evaluate', \"infusion-related risks. It is at investigator's discretion to treat or not\", 'treat patient with alemtuzumab after clinical evaluation. Physician', 'should also apply the following contraindications when treating', 'patients in this study:', 'Hypersensitivity to the active substance, or to any of the', 'excipients', 'Human Immunodeficiency Virus (HIV) infection', 'Severe active infection', 'Uncontrolled hypertension', 'History of arterial dissection of the cervicocephalic arteries', 'History of stroke', 'History of angina pectoris or myocardial infarction', 'Known coagulopathy or on concomitant anti-coagulant therapy', 'Deleted review of HCP checklist.', 'Updated the during infusion with following text:', 'The following are recommendations in case of clinical', 'abnormities/severe adverse event:', '-', 'Interrupt infusion', '-', 'Medically evaluate the patient guided by the adverse event', 'profile of alemtuzumab prior to considering restarting therapy', '-', 'Provide appropriate treatment as needed', '-', 'Consider permanently discontinuing the alemtuzumab infusion', 'if the patient shows clinical symptoms suggesting development', 'of a serious adverse event associated with the infusion', '(myocardial ischemia, hemorrhagic stroke, cervico-cephalic', 'arterial dissection or pulmonary alveolar hemorrhage).', 'Updated the post infusion with following text:', 'Property of the Sanofi Group - strictly confidential', 'Page 142', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Section No. and name Description of change', 'Brief rationale', '-', 'Observation for infusion reactions is recommended for a', 'minimum of 2 hours after alemtuzumab infusion; 2 hours after', 'infusion, patients should be cautious and reporting if any of the', 'infusion reactions develop within 48 hours.', '-', 'Patients with clinical symptoms suggesting development of a', 'serious adverse event temporarily associated with the infusion', '(myocardial ischemia, hemorrhagic stroke, cervico-cephalic', 'arterial dissection or pulmonary alveolar hemorrhage) should', 'be closely monitored until complete resolution of the', 'symptoms. The observation time should be extended as', 'appropriate.', '-', 'The patients should be educated on the potential for delayed', 'onset of infusion associated reactions and symptoms and', 'signs of cardiovascular or cerebrovascular events, and', 'instructed to report symptoms and/or seek appropriate medical', 'care.', 'Section 10.4.1.3 Adverse', 'Added following AESIs:', 'Update of the safety', 'event of special interest', 'Autoimmune mediated conditions including but not limited', 'information following', 'to autoimmune hepatitis, acquired Hemophilia A', 'the Article 20', 'Procedure.', 'Temporally associated* pulmonary alveolar hemorrhage', 'Temporally associated* myocardial ischemia, myocardial', 'infarction', 'Temporally associated* stroke', 'Temporally associated* cervicocephalic arterial dissection', '(* Temporally associated: 1 to 3 days after the last', 'infusion)', 'Progressive multifocal leukoencephalopathy (PML)', 'Updated wording of serious and opportunistic infections to below', 'text:', 'Serious infections including serious opportunistic infections (eg,', 'Listeria infections, CMV, EBV), HPV associated with cervical', 'dysplasia', 'Moved cervical dysplasia with HPV.', 'Deleted hemolytic anemia, autoimmune neutropenia, autoimmune', 'pancytopenia', 'Section 10.4.4 Instructions', 'The following old text:', 'Administrative change', 'for reporting serious adverse', 'SEND (preferably by fax or e-mail) a photocopy of all examinations', 'events', 'carried out and the dates on which these examinations were', 'performed, to the representative of the monitoring team whose', 'name, fax number, and email address appear on the clinical trial', \"protocol. Care should be taken to ensure that the patient's identity is\", \"protected and the patient's identifiers in the clinical trial are properly\", 'mentioned on any copy of a source document provided to the', 'Sponsor. For laboratory results, include the laboratory normal', 'ranges.', 'Is replaced by:', 'Property of the Sanofi Group - strictly confidential', 'Page 143', 'VV-CLIN-0254406 5.0']\n\n###\n\n", "completion": "END"}